Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 12Genitourinary 11Tumor-Agnostic 4Thoracic 3Breast 3Sarcoma 2Head & Neck 2Gastrointestinal 2CNS 2Endocrine 1

Conditions

Small Cell Lung Carcinoma 1Lung Neoplasms 1Carcinoma, Neuroendocrine 1

Interventions

Magnetic Resonance Spectroscopy 15lutetium Lu 177 dotatate 14Specimen Handling 14cabozantinib 10Nivolumab 10Everolimus 8pembrolizumab 7gallium Ga 68 dotatate 6Ipilimumab 6Cisplatin 5Carboplatin 5trametinib 4olaparib 4lenvatinib 4X-Rays 4Lutetium-177 4Etoposide 4Cyclophosphamide 4CTLA-4 Antigen 4fluorodopa F 18 3fludarabine 3dabrafenib 3cemiplimab 3Temozolomide 3Phantoms, Imaging 3Fluorodeoxyglucose F18 3Blood Specimen Collection 3177Lu-octreotide, DOTA(0)-Tyr(3)- 3selpercatinib 2lanreotide 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
niraparib × Endocrine × 90 days × Clear all
NCT04701307 2026-04-22

Niraparib and Dostarlimab for the Treatment of Small Cell Lung Cancer and Other High-Grade Neuroendocrine Carcinomas

M.D. Anderson Cancer Center

Phase 2 Active not recruiting
48 enrolled
EndocrineThoracic

Lung Neoplasms, Carcinoma, Neuroendocrine, Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡